BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bewersdorf JP, Carraway H, Prebet T. Emerging treatment options for patients with high-risk myelodysplastic syndrome. Ther Adv Hematol 2020;11:2040620720955006. [PMID: 33240476 DOI: 10.1177/2040620720955006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Piñero P, Morillas M, Gutierrez N, Barragán E, Such E, Breña J, García-Hernández MC, Gil C, Botella C, González-Navajas JM, Zapater P, Montesinos P, Sempere A, Tarín F. Identification of Leukemia-Associated Immunophenotypes by Databaseguided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia. Cancers (Basel) 2022;14:4010. [PMID: 36011002 DOI: 10.3390/cancers14164010] [Reference Citation Analysis]
2 Lee S, Mohan S, Knupp J, Chamoun K, de Jonge A, Yang F, Baloglu E, Shah J, Kauffman MG, Shacham S, Bhatnagar B. Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents. J Hematol Oncol 2022;15:103. [PMID: 35922861 DOI: 10.1186/s13045-022-01319-y] [Reference Citation Analysis]
3 Snow A, Zeidner JF. The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype? Ther Adv Hematol 2022;13:20406207221112899. [PMID: 35898435 DOI: 10.1177/20406207221112899] [Reference Citation Analysis]
4 Yan X, Lai B, Zhou X, Yang S, Ge Q, Zhou M, Shi C, Xu Z, Ouyang G. The Differential Expression of CD47 may be Related to the Pathogenesis From Myelodysplastic Syndromes to Acute Myeloid Leukemia. Front Oncol 2022;12:872999. [PMID: 35433462 DOI: 10.3389/fonc.2022.872999] [Reference Citation Analysis]
5 Zamora DI, Patel GS, Grossmann I, Rodriguez K, Soni M, Joshi PK, Patel SC, Shreya D, Sange I. Myelodysplastic Syndromes and Modalities of Treatment: An Updated Literature Review. Cureus 2021;13:e20116. [PMID: 34873563 DOI: 10.7759/cureus.20116] [Reference Citation Analysis]
6 Islam A. Higher-risk myelodysplastic syndrome in an elderly patient: Long-term partial remission with low-dose prednisone, G-CSF, and epoetin alfa. Clin Case Rep 2021;9:e04752. [PMID: 34512981 DOI: 10.1002/ccr3.4752] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Schiffer M, Zhao J, Johnson A, Lee J, Bewersdorf JP, Zeidan AM. The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era. Expert Rev Anticancer Ther 2021;21:989-1002. [PMID: 33853476 DOI: 10.1080/14737140.2021.1918002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bewersdorf JP, Zeidan AM. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Cancers (Basel) 2021;13:1610. [PMID: 33807279 DOI: 10.3390/cancers13071610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bewersdorf JP, Zeidan AM. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon? Best Pract Res Clin Haematol 2021;34:101245. [PMID: 33762100 DOI: 10.1016/j.beha.2021.101245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]